Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Century Therapeutics Inc (NASDAQ: IPSC) was $0.55 for the day, down -4.25% from the previous closing price of $0.57. In other words, the price has decreased by -$4.25 from its previous closing price. On the day, 0.64 million shares were traded. IPSC stock price reached its highest trading level at $0.5781 during the session, while it also had its lowest trading level at $0.5415.
Ratios:
Our analysis of IPSC’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 10.72 and its Current Ratio is at 10.72. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rodman & Renshaw on August 08, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On August 28, 2023, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $28 to $5.
On December 27, 2022, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $19.Chardan Capital Markets initiated its Buy rating on December 27, 2022, with a $19 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 18 ’25 when Pfeiffenberger Brent bought 30,745 shares for $0.57 per share.
Carr Douglas sold 296 shares of IPSC for $158 on Aug 04 ’25. The SVP Finance & Operations now owns 405,686 shares after completing the transaction at $0.53 per share. On Jun 09 ’25, another insider, Carr Douglas, who serves as the SVP Finance & Operations of the company, sold 4,904 shares for $0.62 each. As a result, the insider received 3,050 and left with 405,982 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IPSC now has a Market Capitalization of 47514008 and an Enterprise Value of -59718844. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.42 while its Price-to-Book (P/B) ratio in mrq is 0.23. Its current Enterprise Value per Revenue stands at -0.523 whereas that against EBITDA is 3.613.
Stock Price History:
The Beta on a monthly basis for IPSC is 1.79, which has changed by -0.69273746 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, IPSC has reached a high of $2.05, while it has fallen to a 52-week low of $0.34. The 50-Day Moving Average of the stock is -4.31%, while the 200-Day Moving Average is calculated to be -28.50%.
Shares Statistics:
IPSC traded an average of 979.22K shares per day over the past three months and 775220 shares per day over the past ten days. A total of 86.32M shares are outstanding, with a floating share count of 43.09M. Insiders hold about 50.12% of the company’s shares, while institutions hold 23.59% stake in the company. Shares short for IPSC as of 1753920000 were 1339000 with a Short Ratio of 1.37, compared to 1751241600 on 1494787. Therefore, it implies a Short% of Shares Outstanding of 1339000 and a Short% of Float of 2.32.
Earnings Estimates
The performance of Century Therapeutics Inc (IPSC) in the stock market is under the watchful eye of 3.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.26 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$0.13 and -$0.27 for the fiscal current year, implying an average EPS of -$0.22. EPS for the following year is -$1.46, with 3.0 analysts recommending between -$1.14 and -$1.68.
Revenue Estimates
A total of 2 analysts have provided revenue estimates for IPSC’s current fiscal year. The highest revenue estimate was $109.16M, while the lowest revenue estimate was $109.16M, resulting in an average revenue estimate of $109.16M. In the same quarter a year ago, actual revenue was $6.59M
